Use of Retained Earnings and Flexible Share Repurchases
First written in FY2016. 18 of 26 entries say "Advanced", first in FY2018-Q2. Latest entry: 2026-10-23.
- 2026-10-23Advanceds.kabutan.jp
「同時に上限を４００万株（自己株式を除く発行済み株数の１．９５％）、または１００億円を上限として自社株買いを実施すると発表した。」
自己株式取得について、新たな取得枠、取得期間、取得株式の全株式消却が具体的に決定された。 - FY2026AdvancedAnnual report
「During the fiscal year, the company acquired 3,251,000 treasury shares for ¥7,999,832,693 and cancelled 3,251,000 treasury shares.」
Based on the resolution of May 2025, the company acquired 3,251,000 treasury shares for approximately ¥8 billion and cancelled the same number on 28 November 2025. - FY2026-H1AdvancedAnnual report
「Expenditures for the acquisition of treasury shares △ 6,420」
During the interim consolidated accounting period, the company recorded ¥6,420 million in expenditures for the acquisition of treasury shares. Acquisition expenditures increased from ¥5,068 million in the same period of the previous year, and the company continues to acquire treasury shares. - FY2025AdvancedAnnual report
「During the fiscal year, the company acquired 2,065,300 treasury shares for ¥4,999,825,755 and cancelled 2,065,300 treasury shares.」
Regarding the acquisition and cancellation of up to 2.5 million shares and ¥5 billion in treasury shares resolved in May 2024, the company acquired 2,065,300 shares and cancelled the same number. In addition, in May 2025, it resolved on the next acquisition and cancellation, capped at 4 million shares and ¥8 billion. - FY2025-H1AdvancedAnnual report
「Expenditures for the acquisition of treasury shares: ¥5,068 million.」
During the interim consolidated accounting period, the company recorded ¥5,068 million in expenditures for the acquisition of treasury shares. - FY2025-H1AdvancedAnnual report
「Change in total issued shares: down 2,065,300 shares. (Note) The decrease resulted from the cancellation of treasury shares.」
The company disclosed that total issued shares decreased as a result of the cancellation of 2,065,300 treasury shares. - FY2025-H1AdvancedAnnual report
「Expenditures for the acquisition of treasury shares: ¥5,068 million. Change in total issued shares: down 2,065,300 shares. (Note) The decrease resulted from the cancellation of treasury shares.」
During the interim consolidated accounting period, the company recorded ¥5,068 million in expenditures for the acquisition of treasury shares and disclosed a decrease in total issued shares resulting from the cancellation of 2,065,300 treasury shares. - FY2024AchievedAnnual report
「Regarding the acquisition and cancellation of treasury shares during the fiscal year, the company resolved at a meeting of the Board of Directors held on 12 May 2023 to acquire and cancel up to 5.8 million shares and ¥10 billion in value. During the fiscal year, it acquired 4,171,900 treasury shares for ¥9,999,856,522 and cancelled 4,171,900 treasury shares.」
Regarding the acquisition and cancellation of treasury shares resolved in May 2023, the company acquired 4,171,900 shares and cancelled the same number, completing the plan. - FY2024-Q3AdvancedAnnual report
「As the company cancelled treasury shares on 29 December 2023 based on a resolution of the Board of Directors held on 12 May 2023, the total number of issued shares decreased by 4,171,900 shares.」
Regarding the cancellation of treasury shares, the company cancelled 4,171,900 shares on 29 December 2023 based on the resolution of 12 May 2023. The balance of treasury shares was ¥21,254 million. - FY2024-Q2AdvancedAnnual report
「Cash flows from financing activities decreased by ¥12,738 million (compared with a decrease of ¥6,683 million in the same period of the previous year). This was mainly due to ¥5,983 million in expenditures for the acquisition of treasury shares and ¥6,099 million in dividends paid.」
The company acquired treasury shares and recorded ¥5,983 million in expenditures during the cumulative second quarter. - FY2023AchievedAnnual report
「The treasury shares cancelled during the fiscal year were cancelled on 28 February 2023 pursuant to a resolution of the Board of Directors held on 1 February 2023.」
The cancellation of 19,061,254 treasury shares resolved and scheduled in the previous filing was completed on 28 February 2023. In addition, on 12 May 2023, the company resolved to acquire and cancel treasury shares for up to ¥1 billion. - FY2023-Q3AdvancedAnnual report
「At a meeting of the Board of Directors held on 1 February 2023, the company resolved, pursuant to Article 178 of the Companies Act, to cancel treasury shares. Total number of shares to be cancelled: 19,061,254 shares (7.80% of the total number of issued shares before the cancellation). Scheduled cancellation date: 28 February 2023.」
The company resolved to cancel 19,061,254 treasury shares, representing 7.80% of total issued shares, on 28 February 2023. The cancellation was at the resolution and scheduled stage; completion was not stated. - FY2021RestatedAnnual report
「The company will also carry out acquisitions of treasury shares and other measures flexibly and appropriately, taking into consideration its financial condition, share price trends and other factors, in order to implement a flexible capital policy in response to changes in the business environment.」
The company continues to pursue a policy of using retained earnings to deepen and expand its business while considering treasury share acquisitions flexibly. - FY2020-Q3RestatedAnnual report
「Based on a resolution of the Board of Directors held on 31 July 2019, the company acquired 12,500,018 treasury shares. As a result, treasury shares increased by ¥28,137 million during the cumulative third quarter.」
Regarding the treasury share acquisition disclosed in the previous quarter, the company again stated that it had acquired 12,500,018 shares, resulting in an increase of ¥28,137 million. - FY2020-Q2AdvancedAnnual report
「Based on a resolution of the Board of Directors held on 31 July 2019, the company acquired 12,500,018 treasury shares. As a result, treasury shares increased by ¥28,137 million during the cumulative second quarter.」
Regarding the treasury share acquisition policy specified in the previous quarter, the company acquired 12,500,018 shares and recorded ¥28,137 million for the acquisition. - FY2020-Q1AdvancedAnnual report
「As a result, the company concluded that acquiring the shares as treasury shares would contribute to improving capital efficiency, including earnings per share (EPS) and return on equity (ROE), and would lead to the return of profits to shareholders. After thorough consideration of the specific acquisition method from the perspectives of equality among shareholders and transaction transparency, the company determined that a tender offer was appropriate.」
The company decided to conduct a tender offer for treasury shares covering shares held by Takeda Pharmaceutical Company Limited. The details were set as a maximum of 12,500,100 shares, a maximum total acquisition price of ¥28,137,725,100, and an acquisition period from 1 August 2019 to 30 September 2019. - FY2019-Q3RestatedAnnual report
「This was mainly due to an increase of ¥20,418 million in retained earnings, a decrease of ¥6,049 million resulting from the acquisition of treasury shares, a decrease of ¥8,476 million in valuation difference on other securities, and an increase of ¥6,133 million in non-controlling interests.」
As a factor in the change in net assets at the end of the third quarter, the company recorded a ¥6,049 million decrease resulting from the acquisition of treasury shares. - FY2019-Q2AdvancedAnnual report
「Cash flows from financing activities decreased by ¥11,505 million (compared with an increase of ¥1,699 million in the same period of the previous year). This was mainly due to ¥6,059 million in expenditures for the acquisition of treasury shares and ¥5,094 million in dividends paid.」
The company recorded ¥6,059 million in expenditures for the acquisition of treasury shares during the cumulative second quarter and carried out the share acquisition. - FY2019-Q1AdvancedAnnual report
「This was mainly due to an increase of ¥4,064 million in retained earnings, a decrease of ¥6,048 million resulting from the acquisition of treasury shares, an increase of ¥1,854 million in valuation difference on other securities, and an increase of ¥3,195 million in non-controlling interests.」
The company recorded a ¥6,048 million decrease in net assets resulting from the acquisition of treasury shares in the first quarter and carried out the share acquisition. - FY2018AdvancedAnnual report
「To fund the acquisition of shares in JCR Pharmaceuticals, Inc., share repurchases and other purposes, we issued ¥30,750 million of euro-yen convertible bonds with stock acquisition rights and a call option, due 2022, in October 2017.」
Convertible bonds were issued to fund growth investments and share repurchases, and ¥2,935 million was spent on share repurchases. - FY2018-Q2AdvancedAnnual report
「This was primarily attributable to an increase of ¥9,873 million in borrowings, expenditure of ¥2,933 million on share repurchases, and dividend payments of ¥4,510 million.」
Share repurchases were conducted, resulting in expenditure of ¥2,933 million during the cumulative second-quarter consolidated period. - FY2016First statedAnnual report
「We will use retained earnings effectively for purposes including promoting reforms to deepen and expand our businesses so that they can adapt to change. We will also implement share repurchases and other measures appropriately, taking into consideration the financial position, share price trends and other factors, in order to pursue a flexible capital policy that responds to changes in the business environment.」
Retained earnings will be used to deepen and expand the businesses, while share repurchases will be conducted flexibly after taking into consideration the financial position, share price and other factors.